Don’t let chronic inflammation control your life. We help eligible patients access Rinvoq (upadacitinib) for as little as $69.95 per month through manufacturer Patient Assistance Programs.
The Rinvoq Prescription Assistance Program is a manufacturer-sponsored initiative that provides Rinvoq at no medication cost to qualifying patients who cannot afford it. The program provides up to 12 months of medication at no cost if approved, and patients can reapply as needed. Patients with insurance or Medicare Part D may also be eligible as exceptions on a case-by-case basis.
The Rinvoq Prescription Assistance Program is a manufacturer-sponsored initiative that provides Rinvoq at no medication cost to qualifying patients who cannot afford it. The program provides up to 12 months of medication at no cost if approved, and patients can reapply as needed. Patients with insurance or Medicare Part D may also be eligible as exceptions on a case-by-case basis.
AffordMyPrescriptions ensures cost never stands between you and the treatment that could transform your quality of life. For a flat $69.95 per month, our Patient Advocates manage every step of your enrollment, including specialty pharmacy coordination.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$6,500.00 | Save ~$6,430/mo |
| CVS Pharmacy | ~$6,245.00 | Save ~$6,175/mo |
| Walmart | ~$6,400.00 | Save ~$6,330/mo |
| Costco | ~$6,350.00 | Save ~$6,280/mo |
| Kroger | ~$6,300.00 | Save ~$6,230/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
When you live with a chronic autoimmune condition that hasn’t responded to first-line treatments, and your specialist prescribes Rinvoq as the next step, the last thing you need is to spend weeks navigating prior authorization requirements, specialty pharmacy logistics, and copay card enrollment while your disease continues to damage your joints, gut, or skin.
Our trained Patient Advocates understand the unique complexities of specialty medication access — including prior authorization, step therapy documentation, and specialty pharmacy coordination — and manage every detail on your behalf. Because Rinvoq is dispensed through specialty pharmacies, your advocate also coordinates pharmacy logistics for seamless delivery.
Our pricing is simple and predictable: $69.95 per month — every month. While the medication itself is provided at no cost through the manufacturer’s program, our monthly fee covers all advocacy, application management, specialist coordination, and refill oversight. If we’re unable to secure access, you won’t be charged.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through Afford My Prescriptions is the better long-term solution:
Cards expire and require constant renewal
Fixed $69.95/month — never changes regardless of retail price
Medication supplied directly from the manufacturer
Eligibility is generally determined by annual household income levels. Most programs follow guidelines that include a limit of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Patients with insurance or Medicare Part D may also be eligible as exceptions on a case-by-case basis.
Rinvoq (upadacitinib) is a once-daily prescription extended-release tablet used to treat multiple inflammatory and autoimmune conditions in adults and certain children. Rinvoq is FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, giant cell arteritis, atopic dermatitis (severe eczema), ulcerative colitis, and Crohn’s disease. It is available in 15 mg, 30 mg, and 45 mg extended-release tablets, and as an oral liquid solution.
How It Works:
Inside your cells, Janus kinase (JAK) enzymes act as switches that relay inflammatory signals to the nucleus. In autoimmune diseases, these signals are overactive, causing the immune system to attack healthy tissue. Rinvoq selectively blocks JAK1, interrupting this chain reaction before it can activate the genes responsible for inflammation and damage.
Form and Use:
This medication is available as an oral liquid solution or as extended-release tablets in 15 mg, 30 mg, and 45 mg doses. It is taken once daily, with or without food, as directed by a healthcare provider. It is generally prescribed for patients who have not seen success with other treatments, such as TNF blockers.
Generic Availability:
There is currently no generic version of Rinvoq available in the United States as of April 2026. Because the medication is still under patent protection, a generic alternative is unlikely to be released for several years. While the brand-name cost is high, patient assistance programs can help eligible individuals access the medication at a significantly reduced monthly rate.
Warnings:
Rinvoq includes a boxed warning due to risks of serious infections, malignancy, major cardiovascular events, and thrombosis. It is essential to inform your doctor of all medical conditions and current infections before starting treatment. Patients should never stop taking the medication without direct medical supervision.
The average retail price is approximately $6,245–$9,640 per month for 30 tablets, totaling $75,000–$115,000+ per year. The manufacturer offers a $0 copay savings card for commercially insured patients (max $14,000/year). Through AffordMyPrescriptions, qualifying patients receive Rinvoq at no medication cost — our $69.95 monthly fee covers advocacy and program management.
Yes. The Rinvoq supplied through the Patient Assistance Program is the same FDA-approved upadacitinib medication dispensed at specialty pharmacies, supplied directly from the manufacturer.
No. Rinvoq is patent-protected, and no generic is expected to become available for several years.
Patients with insurance or Medicare Part D may be eligible for the PAP as exceptions on a case-by-case basis. Medicare Part D plans also have a $2,100 annual out-of-pocket cap as of 2026. Our advocates can evaluate your situation.
Rinvoq is FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, giant cell arteritis, atopic dermatitis (severe eczema), ulcerative colitis, and Crohn’s disease. It is also approved for polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children 2 years and older.
Our Patient Advocates will immediately explore every alternative — including the manufacturer’s $0 copay savings card, independent co-pay assistance foundations, insurance prior authorization and formulary exception appeals, the Medicare Part D $2,100 annual out-of-pocket cap, and alternative treatments including injectable biologics, other JAK inhibitors, or conventional therapies.
If you are struggling with the high cost of Rinvoq, our team may be able to help you access assistance programs designed to make medications more affordable. Check your eligibility today and take the first step toward reducing your prescription costs.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.